达拉非尼和曲美替尼治疗转移性黑色素瘤引起的颅内出血。

IF 1.5 4区医学 Q3 DERMATOLOGY

Melanoma Research Pub Date : 2024-04-05 DOI:10.1097/cmr.0000000000000820

Aymeric Hennemann, Eve Puzenat, Marion Decreuse, Fabrice Vuillier, Charlée Nardin, François Aubin

{"title":"达拉非尼和曲美替尼治疗转移性黑色素瘤引起的颅内出血。","authors":"Aymeric Hennemann, Eve Puzenat, Marion Decreuse, Fabrice Vuillier, Charlée Nardin, François Aubin","doi":"10.1097/cmr.0000000000000820","DOIUrl":null,"url":null,"abstract":"Although generally well tolerated compared with chemotherapy, molecular targeted therapy used in metastatic melanoma may be associated with life-threatening toxicity. We report the case of a patient with metastatic melanoma treated by dabrafenib plus trametinib who developed intracranial hemorrhage. Physicians should be aware of this rare but life-threatening adverse event of B-rapidly accelerated fibrosarcoma (BRAF) and mitogen-activated protein kinase kinase (MEK). However, they should be careful about the bleeding origin, which can prove to be a new onset of melanoma metastasis or anticoagulation overdose, or even an uncontrolled arterial hypertension.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma.\",\"authors\":\"Aymeric Hennemann, Eve Puzenat, Marion Decreuse, Fabrice Vuillier, Charlée Nardin, François Aubin\",\"doi\":\"10.1097/cmr.0000000000000820\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Although generally well tolerated compared with chemotherapy, molecular targeted therapy used in metastatic melanoma may be associated with life-threatening toxicity. We report the case of a patient with metastatic melanoma treated by dabrafenib plus trametinib who developed intracranial hemorrhage. Physicians should be aware of this rare but life-threatening adverse event of B-rapidly accelerated fibrosarcoma (BRAF) and mitogen-activated protein kinase kinase (MEK). However, they should be careful about the bleeding origin, which can prove to be a new onset of melanoma metastasis or anticoagulation overdose, or even an uncontrolled arterial hypertension.\",\"PeriodicalId\":18550,\"journal\":{\"name\":\"Melanoma Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-04-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Melanoma Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/cmr.0000000000000820\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Melanoma Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/cmr.0000000000000820","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

虽然与化疗相比，转移性黑色素瘤的分子靶向治疗通常耐受性良好，但也可能出现危及生命的毒性反应。我们报告了一例接受达拉非尼加曲美替尼治疗的转移性黑色素瘤患者发生颅内出血的病例。医生应该了解这种罕见但危及生命的 B 型快速加速纤维肉瘤（BRAF）和丝裂原活化蛋白激酶激酶（MEK）不良事件。不过，他们应该注意出血的来源，这可能是黑色素瘤转移新发或抗凝剂过量，甚至是未得到控制的动脉高血压。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma.

Although generally well tolerated compared with chemotherapy, molecular targeted therapy used in metastatic melanoma may be associated with life-threatening toxicity. We report the case of a patient with metastatic melanoma treated by dabrafenib plus trametinib who developed intracranial hemorrhage. Physicians should be aware of this rare but life-threatening adverse event of B-rapidly accelerated fibrosarcoma (BRAF) and mitogen-activated protein kinase kinase (MEK). However, they should be careful about the bleeding origin, which can prove to be a new onset of melanoma metastasis or anticoagulation overdose, or even an uncontrolled arterial hypertension.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Melanoma Research 医学-皮肤病学

CiteScore

3.40

自引率

4.50%

发文量

139

审稿时长

6-12 weeks

期刊介绍： Melanoma Research is a well established international forum for the dissemination of new findings relating to melanoma. The aim of the Journal is to promote the level of informational exchange between those engaged in the field. Melanoma Research aims to encourage an informed and balanced view of experimental and clinical research and extend and stimulate communication and exchange of knowledge between investigators with differing areas of expertise. This will foster the development of translational research. The reporting of new clinical results and the effect and toxicity of new therapeutic agents and immunotherapy will be given emphasis by rapid publication of Short Communications. Thus, Melanoma Research seeks to present a coherent and up-to-date account of all aspects of investigations pertinent to melanoma. Consequently the scope of the Journal is broad, embracing the entire range of studies from fundamental and applied research in such subject areas as genetics, molecular biology, biochemistry, cell biology, photobiology, pathology, immunology, and advances in clinical oncology influencing the prevention, diagnosis and treatment of melanoma.